Novel therapies for certain autoimmune diseases have been developed to end B cell-driven immune attacks on normal tissues. B cell development and function is regulated through many pathways, offering ...
Eligible patients were randomly assigned (2:1) to receive either durvalumab or placebo administered from the start of cCRT. Patients without progression after completing cCRT received consolidation ...
Study design, end points, and statistical analysis for REACH2 (ClinicalTrials.gov identifier: NCT02913261) have been reported previously. 12 Briefly, 309 patients were randomly assigned (1:1) to ...
Adocia and Tonghua Dongbao have announced positive topline results from a phase 3 clinical trial of BioChaperone Lispro (THDB0206 injection), an ultra-rapid insulin formulation, in adults with type 1 ...
Novartis (NVS) today announced that Cosentyx met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial. Cosentyx demonstrated statistically significant and clinically ...
Brexafemme (ibrexafungerp) partners GSK and Scynexis have worked out their quarrel related to a clinical trial that was previously put on hold, leaving Scynexis with a $22 million payout. Per the ...
Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...
New York, USA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The melanoma market is ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Abbisko Cayman Limited ( (HK:2256)) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback